Search results
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 10 hours agoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript May 8, 2024 Karyopharm...
Q1 2024 Vertex Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 days agoParticipants Charles F. Wagner; Executive VP & CFO; Vertex Pharmaceuticals Incorporated Reshma Kewalramani; CEO, President & Director; Vertex Pharmaceuticals Incorporated ...
Karyopharm Therapeutics Inc [KPTI] Insider Rangwala Reshma sells 6,789 Shares – Company Insider...
Knox Daily· 3 days agoKaryopharm Therapeutics Inc’s recent filing unveils that its EVP & Chief Medical Officer Rangwala Reshma unloaded Company’s shares for reported $7943.0 on Apr 22 ’24. In the ...
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 18 hours agoQ: What updates can we expect from the updated C&R data at ASCO regarding the endometrial cancer study? A: Reshma Rangwala, Chief Medical Officer & Head of Research, mentioned ...
Inaugural Moms First Summit Aims To Finish The Fight For Gender Equality
Forbes· 20 hours agoMoms First launches its inaugural Summit aimed at revolutionizing the narrative around motherhood and empowering moms across the nation. The summit will feature some of the most influential ...
Chinese Stocks Are Bouncing Back. Why You Should Wait.
Barrons.com· 2 days agoAlso potentially attractive buys: Battered internet companies like Alibaba, Tencent and JD.com that...
Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
GuruFocus.com via Yahoo Finance· 3 days agoQ & A Highlights Q: What are the expectations for the sweat chloride benefit in the vanzacaftor triple label? A: Reshma Kewalramani, CEO, President & Director of Vertex, expects ...
Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy...
FierceBiotech· 3 days agoVertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory submission a month ...
High prices for new diabetes drugs are reason for alarm
Futurity· 3 days agoThe implications of high prices for new diabetes and obesity therapies are alarming, according to...
Vertex shares eise on earnings beat
Investing.com· 4 days agoVertex Pharmaceuticals (NASDAQ: VRTX ) Incorporated ( NASDAQ : VRTX) reported a robust first quarter for 2024, surpassing analyst expectations with a 13%...
